Assembling the brief…
The front page of AI-driven biology.
Latest
Every qualified industry development and scientific result, newest first.
Mathur and colleagues fine-tuned foundation-model gene embeddings and used temporal graph neural networks to distinguish treatment-response patterns across four inflammatory diseases.
First author: Sachin MathurLast author: Ziv Bar-Joseph
Affiliations: Sanofi, University of Michigan, GenBio AI
The Gates Foundation committed an initial $20 million—and up to $15 million more—to ProFound Therapeutics for a maternal-health discovery program built around the company’s expanded-proteome platform.
Source: Announcement
More: Fierce Biotech
Hu and colleagues built Coala to expose Common Workflow Language tools to language-model agents through the Model Context Protocol.
First author: Qiang HuLast author: Song Liu
Affiliations: Roswell Park Comprehensive Cancer Center
Ahsan and colleagues trained a contrastive learning model on spatial transcriptomics and tissue images to predict pathway-level expression from routine histology.
First author: Muhammad Ahtazaz AhsanLast author: Syed Murtuza Baker
Affiliations: The University of Manchester
Suga and colleagues combined pretrained RNA-language-model representations with contrastive learning to identify coordinated relationships between 5′ and 3′ untranslated regions.
First author: Kanta SugaLast author: Michiaki Hamada
Affiliations: Waseda University, University of Pennsylvania, National Institute of Advanced Industrial Science and Technology, Nippon Medical School
Researchers closed the loop from genome mining and deep-learning peptide ranking to synthesis and antimicrobial testing against Staphylococcus aureus.
First author: Ojeda, S.Last author: Munoz-Camargo, C.
Affiliations: Universidad de los Andes
Source: bioRxiv preprint
Zhao and colleagues paired protein-language-model design with pooled mammalian-cell screening to identify peptide-guided degraders against four targets.
First author: Lin ZhaoLast author: Pranam Chatterjee
Affiliations: University of Pennsylvania, University of Wisconsin, Children's Hospital of Philadelphia
Source: bioRxiv preprint
Bhattacharya, A. and colleagues report that a data-fusion model projected cortical Alzheimer's signatures across a 108-region whole-brain single-cell atlas.
First author: Bhattacharya, A.Last author: Bzdok, D.
Affiliations: McGill University
Source: bioRxiv preprint
Zhang, S. and colleagues report that dynaTPH adds standardized molecular-dynamics trajectories and biophysical features to 256 representative T-cell-receptor complexes.
First author: Zhang, S.Last author: Fu, L.
Affiliations: Institute of Medical Artificial Intelligence, South China Hospital, Shenzhen University
Source: bioRxiv preprint
Alizada, S. and colleagues classified six cell states from label-free imaging more accurately as additional frames were added using a spatiotemporal neural network.
First author: Alizada, S.Last author: Zangle, T. A.
Affiliations: University of Utah
Source: bioRxiv preprint
Xi, G. reports that scDisent separates expression-linked and regulation-linked variables instead of compressing multi-omic measurements into one latent space.
Author: Xi, G.
Affiliations: Jena University Hospital
Source: bioRxiv preprint
Li, L. and colleagues found that high expression similarity often failed to preserve the drug-response signatures models were meant to predict using a mechanism-aware benchmark.
First author: Li, L.Last author: Fang, B.
Affiliations: MindFlow.ai
Source: bioRxiv preprint
Sallam, A. and colleagues report that an unsupervised stress test separated single-cell foundation models that looked nearly equivalent on standard downstream benchmarks.
First author: Sallam, A.Last author: Gillis, J.
Affiliations: University of Toronto
Source: bioRxiv preprint
Diplock, N. and colleagues report that wet-lab tests found many functional proteins far from known natural sequences while exposing inconsistent predictions from protein language models.
First author: Diplock, N.Last author: Leonard, S. P.
Affiliations: Lawrence Livermore National Laboratory
Source: bioRxiv preprint
Summit and Akeso said ivonescimab plus chemotherapy improved overall survival versus durvalumab plus chemotherapy in a China-based Phase 3 trial, but numerical results remain pending.
Source: Announcement
More: ClinicalTrials.gov record, BioSpace, Fierce Biotech, OncLive
The FDA approved once-daily Rasonque, or daraxonrasib, for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy or when multiagent therapy is not an option.
Source: Announcement
More: Revolution Medicines, Associated Press, BioPharma Dive, Fierce Biotech, Reuters, STAT
Faro announced a $37.3 million Series B co-led by Merck Global Health Innovation Fund and S32, with existing and new investors participating. The company says it will use the financing to expand AI agents for clinical-development workflows.
Source: Announcement
Onos Health raised a $17 million Series A led by Costanoa Ventures, with Flare Capital Partners and CVS Health Ventures participating. The company plans to expand its behavioral-health clinical-intelligence platform and health-plan deployments.
Source: Announcement
General Catalyst led Transfyr's $25 million seed round. The startup uses sensors and multimodal models to record the unwritten details that can determine whether experiments reproduce or transfer between labs.
Source: Announcement
More: The New York Times
LinkedIn: @annamariewagner
SK Biopharmaceuticals agreed to take global rights to Biohaven’s Kv7 platform and opakalim, the Phase 2/3 epilepsy candidate also known as BHV-7000. Biohaven receives $350 million at closing and $50 million in 2027; development, regulatory, and prior-owner obligations account for the rest of the announced value.
Source: Announcement
More: BioPharma Dive, BioSpace
Chen and colleagues used deep learning to design 15 synthetic enhancers that activated the intended tissues in mouse embryos.
First author: Shenzhi ChenLast author: Alexander Stark
Affiliations: Research Institute of Molecular Pathology, Vienna BioCenter PhD Program, University of California, Irvine, Medical University of Vienna
Source: Nature Genetics article
Generate:Biomedicines reported that a single 300-mg dose of GB-0895 suppressed four inflammatory biomarkers for at least six months in a Phase 1 asthma study.
Capital and public listings improved in early 2026, but employment data still reflects the industry's recent contraction.
Source: Announcement
More: BioPharma Dive, Fierce Biotech
The agency moved deramiocel's decision date to November 22 while it reviews new follow-up data and analyses.
Source: Announcement
More: Nippon Shinyaku, Fierce Biotech
Lundbeck is expanding EVERSANA's AI-enabled platform across marketing, medical communications, market access, and media in its U.S. organization. The companies did not disclose financial terms or product-level performance.
Source: Announcement
More: Fierce Pharma
Haisco granted Sentivera rights outside Greater China to a preclinical small molecule for Type 2 inflammatory diseases. Haisco says the package includes $75.89 million in upfront cash and equity consideration, up to $1.46 billion in milestones, and tiered royalties; Fierce Biotech separately reported the transaction.
Source: Announcement
More: Fierce Biotech
Shijie Wan and colleagues report that a sparse-data machine-learning loop helped researchers engineer a compact Fanzor genome editor that worked across mammalian-cell targets and in a mouse experiment.
First author: Shijie WanLast author: Xue Gao
Affiliations: University of Pennsylvania, Rice University
Source: Nature Biotechnology article
More: EvoMax source code
The FcRn blocker becomes the first FDA-approved treatment specifically for adults and adolescents with warm autoimmune hemolytic anemia.
Source: Announcement
More: Fierce Pharma
Hanmi granted Genentech exclusive rights outside South Korea to HM17321, a clinical-stage UCN2 analogue. Hanmi says it will receive $190 million up front, may receive development, regulatory, and commercial milestones that bring the total value to as much as $2.3 billion, and is eligible for tiered sales royalties.
Source: Announcement
More: Fierce Biotech
Lars Schimmelpfennig and colleagues report that a Model Context Protocol server lets language models query current, structured drug-gene interaction data from DGIdb.
First author: Lars SchimmelpfennigLast author: Obi L Griffith
Affiliations: Washington University School of Medicine, Nationwide Children’s Hospital, The Ohio State University College of Medicine
Thi Lan Nguyen and colleagues report that gRASSP combines pretrained RNA representations with lightweight graph refinement for RNA-small molecule binding-site prediction.
First author: Thi Lan NguyenLast author: Nguyen Quoc Khanh Le
Affiliations: The University of Queensland, Taipei Medical University
Yijun Ren and colleagues report that a cross-jurisdiction analysis finds longer second-authorization delays when radiology AI reaches Europe before the United States.
First author: Yijun RenLast author: George CM Siontis
Affiliations: Politecnico di Milano, University of Bern, Bern University Hospital, University Hospital of Wales, IRCCS Istituto Auxologico Italiano
Joao Sartori and colleagues report that enzymARC tests whether enzyme-function predictors reject structure-guided decoys whose catalytic machinery has been disrupted.
First author: Joao SartoriLast author: Lucas de Almeida Machado
Affiliations: Fiocruz, Instituto Oswaldo Cruz, Institute of Technology on Immunobiologicals (Bio-Manguinhos), Fiocruz
Source: bioRxiv preprint version 1
More: EnzymARC repository
The startup wants repeated experiments on viable human skin to improve predictions about how compounds will behave before clinical testing.
Source: TechCrunch profile
Cellares plans to resize after an unnamed large pharmaceutical customer ended a partnership, according to independent reporting.
Gossamer expects $25 million at the initial close. A $125 million second tranche depends partly on FDA acceptance of a seralutinib NDA, while up to $100 million more would require later warrant exercises after approval; some issuance also needs stockholder approval.
Source: Announcement
More: Gossamer Form 8-K
The companies announced an all-stock reverse merger and concurrent $150 million private placement. Closing is expected in the first quarter of 2027 and remains subject to approvals and customary conditions; neridronate remains investigational.
Source: Announcement
More: Fierce Biotech
Jiedan Xiao and colleagues report that a conditional diffusion model reconstructs plausible single-cell populations from bulk-like expression summaries.
First author: Jiedan XiaoLast author: Andreas Raue
Affiliations: University of Augsburg
Source: bioRxiv preprint version 1
Yuyan Chen reports that a DNA foundation model combines sequence with local and global chromatin accessibility while trying to prevent one modality from overwhelming the representation.
Author: Yuyan Chen
Affiliations: ModelsLive Inc.
Source: bioRxiv preprint version 1
The companies announced a research collaboration using Chai's models for antibody discovery. Targets, disease areas, economics, timelines, and candidate-level results were not disclosed.
Source: Announcement
More: Fierce Biotech
M. Frank Erasmus and colleagues report that a prospective, blinded antibody challenge found real pockets of strong performance, but most methods did not generalize across its three tasks.
First author: M. Frank ErasmusLast author: Andrew R. M. Bradbury
Affiliations: Specifica, an IQVIA Business, Carterra, Sapidyne Instruments, Mosaic Biosciences
Source: Nature Biotechnology article
Liron Leibovitch and colleagues report that a four-week emergency-department evaluation found mostly appropriate sampled outputs but falling clinician adoption and no reduction in length of stay.
First author: Liron LeibovitchLast author: Shahar Shelly
Affiliations: Rambam Health Care Campus, Technion – Israel Institute of Technology
Source: Nature Medicine article
More: SHAKED analysis code
Alekhya Kandoor and colleagues report that spY-C learns shared sequence constraints for whether a human phosphotyrosine site can participate in SH2-domain binding.
First author: Alekhya KandoorLast author: Kristen M. Naegle
Affiliations: University of Virginia, University of Southern Denmark, University of Connecticut
Source: bioRxiv preprint
More: SpY-C code
Maximilien Burq and colleagues matched or beat much larger RNA-only models on most reported benchmarks using a small biological foundation model trained with proteomics.
First author: Maximilien BurqLast author: Peter Cimermancic
Affiliations: Tesorai Inc.
Source: bioRxiv preprint version 1
Network Bio paired a $50 million launch financing with plans to build a cell-free RNA foundation model alongside NVIDIA.
The companies say intismeran plus Keytruda met recurrence-free and distant metastasis-free survival endpoints; effect sizes and overall-survival data are not yet available.
Network Bio announced a collaboration combining its longitudinal cell-free RNA datasets with NVIDIA accelerated computing, Parabricks, and BioNeMo Recipes to build a foundation model called Nexus. Financial terms, development milestones, and external validation plans were not disclosed.
Source: Announcement
Julie Liliane Daniel and colleagues report that alphaConformers uses structures from related proteins as template hypotheses to steer AlphaFold2 toward alternative conformations.
First author: Julie Liliane DanielLast author: Diego Javier Zea
Affiliations: I2BC (CNRS, CEA, Université Paris-Saclay)
Source: bioRxiv preprint
More: AlphaConformers code
Hanchen Wang and colleagues report that perturb-ME combines phenotype enrichment, genome-scale CRISPR, and multimodal single-cell readouts to map mechanisms behind a selected phenotype.
First author: Hanchen WangLast author: Aviv Regev
Affiliations: Genentech, Stanford University, Broad Institute of MIT and Harvard
Source: bioRxiv preprint
More: Perturb-ME code
GenScript reported that its AI-enabled drug-discovery business doubled year over year, without disclosing standalone segment revenue.
Source: Announcement
Amylyx reports fewer severe hypoglycemic events with avexitide, while complete arm-level and registry-posted results remain unavailable.
Source: Announcement
Craif announced an approximately $33 million Series D co-led by Granite Integral and Tauns Laboratories. The headline total combines approximately $30.7 million of equity, including a secondary component, with approximately $3.3 million of debt, so it should not be read as entirely new primary equity capital.
Source: Announcement
More: Fierce Biotech financing
Causaly and Syneos Health announced a strategic partnership to apply Causaly's platform across therapeutic-area expertise, medical advisory, real-world evidence, patient advocacy, and proposal development. The companies did not disclose financial terms or implementation milestones.
Source: Announcement
Kareem Al Nahas and colleagues report that pUREdrop automates time-resolved screening of designed proteins inside picoliter synthetic cells, demonstrated with FtsZ variants and modulators.
First author: Kareem Al NahasLast author: Petra Schwille
Affiliations: Max Planck Institute of Biochemistry
Source: Nature Communications article
More: PUREdrop code
A Joint Research Centre report calls for realistic capability claims, transparent reporting, and reproducible validation of biology AI systems.
Source: JRC science-for-policy report
Insilico Medicine launched an informational webpage and previewed a multi-agent virtual-cell concept that treats biological age as a conditioning variable across several biological scales.
Source: Announcement
Genedata announced an AI-guided biomarker workflow inside its commercial Profiler platform, with structured study design, quality control, modeling, and reporting steps.
Source: Announcement
Alvin Hsu and colleagues report that optiPrime uses a mechanism-based machine-learning model to predict prime-editing outcomes and nominate edits intended to evade mismatch repair.
First author: Alvin HsuLast author: David R. Liu
Affiliations: Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Howard Hughes Medical Institute, Harvard University, The Jackson Laboratory
Source: Nature Biotechnology article
More: OptiPrime source code
Yue You and colleagues report that a preprint combines an immune-aging score, a tokenized virtual-cell model, and an agent that revises its own compound-scoring objective.
First author: Yue YouLast author: Luyi Tian
Affiliations: Walter and Eliza Hall Institute of Medical Research, Westlake University, Guangzhou National Laboratory, Rectified Flow Capital Limited
Source: bioRxiv preprint
Infinimmune said it closed a $75 million Series A co-led by Regeneron Ventures and Playground Global. The financing is intended to move its two atopic-dermatitis antibody programs toward first-in-human testing and support additional programs and platform development.
Source: Announcement
More: BioPharma Dive financing
Aureka said it closed a $100 million Series B: Granite Asia exclusively funded the first tranche, while an unnamed strategic investor led a subsequent tranche. The company also named HighLight Capital and existing investors MPCi and NRL as participants; valuation and tranche sizes were not disclosed.
Source: Announcement
Novo Nordisk selected AWS as its preferred cloud provider and strategic AI partner and said the companies will open a co-innovation hub in London. The stated work includes Amazon Bio Discovery, Bedrock, and Bedrock AgentCore; financial terms and delivery milestones were not disclosed.
RSNA opened a multimodal knee-MRI challenge using images and radiology-report text from sites across five continents, with an expert-annotated evaluation set.
Source: Announcement
More: RSNA AI challenge page